S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:ARNA

Arena Pharmaceuticals News Headlines

$49.55
-3.62 (-6.81%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$48.43
$53.91
50-Day Range
$49.55
$63.74
52-Week Range
$45.50
$85.00
Volume
779,533 shs
Average Volume
414,183 shs
Market Capitalization
$3.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.37

Media Mentions By Week



Arena Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARNA
News Sentiment

0.15

0.32

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARNA Articles
This Week

6

1

ARNA Articles
Average Week

Get Arena Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

Arena Pharmaceuticals (NASDAQ:ARNA) News Headlines Today

SourceHeadline
marketbeat.com logoSVB Leerink Reiterates Buy Rating for Arena Pharmaceuticals (NASDAQ:ARNA)
marketbeat.com - December 1 at 7:16 AM
finance.yahoo.com logoEven with Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock down 6.9% this week, insiders who bought recently netted around US$12k
finance.yahoo.com - December 1 at 9:48 AM
MarketBeat logoArena Pharmaceuticals (NASDAQ:ARNA) Rating Reiterated by SVB Leerink
americanbankingnews.com - December 1 at 9:40 AM
finance.yahoo.com logoArena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
finance.yahoo.com - November 19 at 9:07 AM
MarketBeat logoArena Pharmaceuticals (NASDAQ:ARNA) Shares Gap Down to $59.94
americanbankingnews.com - November 18 at 11:35 AM
MarketBeat logoZacks: Brokerages Anticipate Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to Announce -$2.46 Earnings Per Share
americanbankingnews.com - November 11 at 11:18 PM
MarketBeat logoCatalyst Pharmaceuticals (NASDAQ:CPRX) and Arena Pharmaceuticals (NASDAQ:ARNA) Head-To-Head Survey
americanbankingnews.com - November 10 at 3:16 PM
markets.businessinsider.com logoHere's what Wall Street expects from Arena Pharmaceuticals's earnings
markets.businessinsider.com - November 5 at 9:27 PM
uk.finance.yahoo.com logoArena Pharmaceuticals, Inc. (ARNA) Reports Q3 Loss, Lags Revenue Estimates
uk.finance.yahoo.com - November 5 at 4:26 PM
finance.yahoo.com logoArena (ARNA) Q3 Loss Wider Than Anticipated, Revenues Nil
finance.yahoo.com - November 5 at 4:26 PM
fool.com logoArena Pharmaceuticals, inc (ARNA) Q3 2021 Earnings Call Transcript
fool.com - November 5 at 12:09 AM
finance.yahoo.com logoArena Reports Third Quarter Financial Results and Key Program Updates
finance.yahoo.com - November 4 at 7:32 PM
finance.yahoo.com logo11 Best Hemp Stocks To Buy Now
finance.yahoo.com - October 29 at 6:11 AM
finance.yahoo.com logoArena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
finance.yahoo.com - October 14 at 5:35 PM
finance.yahoo.com logoHedge Funds Are Coming Back To Arena Pharmaceuticals, Inc. (ARNA)
finance.yahoo.com - October 12 at 8:41 AM
finance.yahoo.com logoBullish Sentiment Across The Cannabis Space - Check Full Movers For September 2, 2021
finance.yahoo.com - September 2 at 11:15 PM
finance.yahoo.com logoArena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
finance.yahoo.com - September 2 at 6:15 PM
finance.yahoo.com logoArena Pharma, GrowGen & HEXO Among Top Cannabis Stock Movers On August 23, 2021
finance.yahoo.com - August 24 at 3:24 AM
nasdaq.com logoArena Pharmaceuticals Inc Shares Fall 0.3% Below Previous 52-Week Low - Market Mover
nasdaq.com - August 19 at 3:13 AM
nasdaq.com logoArena Pharmaceuticals Inc Shares Fall 3.0% Below Previous 52-Week Low - Market Mover
nasdaq.com - August 11 at 3:52 AM
nasdaq.com logoOversold Conditions For Arena Pharmaceuticals (ARNA)
nasdaq.com - August 9 at 9:05 PM
finance.yahoo.com logoArena Pharmaceuticals, inc (ARNA) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 6 at 1:23 PM
finance.yahoo.com logoArena Pharmaceuticals, Inc. (ARNA) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 5 at 10:48 PM
finance.yahoo.com logoArena Reports Second Quarter Financial Results and Key Program Updates
finance.yahoo.com - August 5 at 5:47 PM
finance.yahoo.com logoSecond Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
finance.yahoo.com - August 5 at 7:46 AM
finance.yahoo.com logoArena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
finance.yahoo.com - July 29 at 7:16 PM
finance.yahoo.com logoArena Pharma In-Licenses Aristea's CXCR2 Antagonist For Immune-Mediated Inflammatory Diseases
finance.yahoo.com - July 28 at 2:16 PM
msn.com logoThe Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
msn.com - July 28 at 9:15 AM
finance.yahoo.com logoArena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
finance.yahoo.com - July 27 at 5:21 PM
finance.yahoo.com logoArena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
finance.yahoo.com - July 19 at 9:08 AM
nasdaq.com logoArena Pharmaceuticals, Inc. Common Stock (ARNA)
nasdaq.com - July 16 at 12:10 AM
finance.yahoo.com logoHedge Funds Are Dumping Arena Pharmaceuticals, Inc. (ARNA)
finance.yahoo.com - July 6 at 1:50 PM
nasdaq.com logoARNA Makes Bullish Cross Above Critical Moving Average
nasdaq.com - June 25 at 6:05 PM
finance.yahoo.com logoSteven Schoch Elected to Arena Pharmaceuticals Board of Directors
finance.yahoo.com - June 14 at 1:01 PM
finance.yahoo.com logoArena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
finance.yahoo.com - June 10 at 1:31 PM
finance.yahoo.com logoArena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
finance.yahoo.com - June 9 at 9:19 AM
finance.yahoo.com logoArena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)
finance.yahoo.com - June 8 at 8:37 AM
nasdaq.com logoArena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) CEO Compensation Looks Acceptable To Us And Here's Why
nasdaq.com - June 5 at 12:17 PM
finance.yahoo.com logoThis Is Why Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) CEO Compensation Looks Appropriate
finance.yahoo.com - June 5 at 12:17 PM
finance.yahoo.com logoWhy Is Arena Pharmaceuticals, Inc. (ARNA) Down 2.8% Since Last Earnings Report?
finance.yahoo.com - June 4 at 4:09 PM
finance.yahoo.com logoArena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
finance.yahoo.com - June 3 at 12:36 PM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Arena Pharmaceuticals, Inc.'s (NASDAQ:ARNA) Share Registry?
finance.yahoo.com - May 17 at 9:03 AM
seekingalpha.com logoArena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 12:29 PM
nasdaq.com logoArena Pharmaceuticals is Now Oversold (ARNA)
nasdaq.com - May 6 at 9:22 PM
finance.yahoo.com logoArena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses
finance.yahoo.com - May 6 at 4:21 PM
finance.yahoo.com logoArena Pharmaceuticals Inc (ARNA) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 6 at 5:09 AM
finance.yahoo.com logoArena Pharmaceuticals, Inc. (ARNA) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 5 at 11:28 PM
finance.yahoo.com logoArena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter
finance.yahoo.com - May 5 at 6:28 PM
finance.yahoo.com logoArena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
finance.yahoo.com - April 28 at 7:47 PM
businesswire.com logoArena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking ...
businesswire.com - April 23 at 10:47 PM
finance.yahoo.com logoArena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX
finance.yahoo.com - April 23 at 12:46 PM
Get Arena Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.